News

Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China

logo-glyco

Rockville biotech GlycoMimetics Inc. has entered into a license agreement worth $189 million or more with a West Coast company. The deal gives cancer therapy biopharma Apollomics Inc. of Foster City, California exclusive rights to develop and commercialize GlycoMimetics’ blood cancer drug in greater China, which encompasses mainland China, Hong Kong, Taiwan and Macau, the […]

Comments Off on Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China Continue Reading →

Technical.ly Baltimore: MTC's Martin Rosendale, UM BioPark's James Hughes and Others Share Their Thoughts on Baltimore's Imagined Future

TechBmore2-1180x600

Imagined futures: Baltimore tech and biz leaders tell us what they envision for the next decade The year is winding down, which offers time to pause and look back at how we were moving, reading, hiring and exiting in 2019. But in this case, it’s not just about one year: The coming calendar turnover marks […]

Comments Off on Technical.ly Baltimore: MTC's Martin Rosendale, UM BioPark's James Hughes and Others Share Their Thoughts on Baltimore's Imagined Future Continue Reading →

MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update

Shruti A 2X2 Final Maxcyte Portrait Dec 2019 DSC_6560 Coyle Studios

– Shrut Abbato will lead development of new partnerships for the Company’s CARMA platform programs – Phase I trial of lead CARMA candidate MCY-M11 remains on-track with the dosing of the third cohort of patents underway and no dose-limitng toxicites or related serious adverse events observed Gaithersburg, Maryland – DECEMBER 19, 2019: MaxCyte, the global clinical-stage […]

Comments Off on MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update Continue Reading →

Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair

MHeffernan_Headshot

Cambridge, MA, December 17, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today announced that Michael Heffernan has joined the Board of Directors as Chairman. “Indalo’s unique approach to treating fibrosis, combined with a highly […]

Comments Off on Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair Continue Reading →

BioBuzz: Cartesian Therapeutics CEO Dr. Murat Kalayoglu Participates in "CEO Talk" Panel

Murat

After Leading a Dozen Startups Here is What Four Biotech Founders Had to Share About Their Success In the heart of Montgomery County, Maryland’s premier biotech district there is a 42,000 SF facility with 17,000 SF vacant lab/office suite located at 9900 Medical Center Drive. The newly delivered and available lab space was designed to foster collaboration […]

Comments Off on BioBuzz: Cartesian Therapeutics CEO Dr. Murat Kalayoglu Participates in "CEO Talk" Panel Continue Reading →

Technical.ly Baltimore: UMB Licenses Technology to Y Combinator-backed Biotech Startup

Ritu_headshot_2019-e1575410514124

A biotech startup that’s backed by Silicon Valley’s well-known Y Combinator accelerator has ties to Baltimore: GEn1E Lifesciences is working to commercialize a treatment for inflammatory and age-related diseases that was developed at the University of Maryland, Baltimore, and is partnering with a Baltimore-based startup that also grew out of UMB collaboration. On Tuesday, UMB said it granted GEn1E Lifesciences the […]

Comments Off on Technical.ly Baltimore: UMB Licenses Technology to Y Combinator-backed Biotech Startup Continue Reading →

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs

Maxcyte logo square

Gaithersburg, MD and Cambridge, MA – December 4, 2019: MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement. Under the agreement, […]

Comments Off on MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs Continue Reading →

GEn1E Lifesciences Granted Exclusive License for UMB Drug Portfolio Compound

umventures-logo-trans

PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and all-fields license to the University of Maryland, Baltimore’s (UMB) specific and function selective p38a kinase inhibitor program. GEn1E is developing cures […]

Comments Off on GEn1E Lifesciences Granted Exclusive License for UMB Drug Portfolio Compound Continue Reading →

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer

Maxcyte logo square

– Clinical and commercial agreement using MaxCyte’s recently launched ExPERT™ platform – Takes MaxCyte’s total number of partnered commercial licenses to seven CAMBRIDGE, Mass. & GAITHERSBURG, Md., (November 21, 2019)— Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and MaxCyte, Inc., a global cell-based therapies and life sciences […]

Comments Off on Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer Continue Reading →

Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965

Indalo

Demonstrates strong safety and oral PKData presented November 7, 2019 at PFF Summit, San Antonio, TX Cambridge, MA, November 11, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), for the first time presented clinical data […]

Comments Off on Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965 Continue Reading →